Deriving income from letting somebody else pursue a direction you weren't prioritizing is always a good business strategy, which is what Tesaro Inc. did by out-licensing niraparib in prostate cancer to Janssen Biotech Inc. while retaining all other rights to the poly ADP-ribose polymerase (PARP) inhibitor.
Competition among PARP inhibitor developers was heightened when AstraZeneca PLC obtained limited US FDA approval for Lynparza (olaparib) in third-line...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

